These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 9354689

  • 1. IRC011, a new synthetic chelator with selective interaction with catabolic red blood cell iron: evaluation in hypertransfused rats with hepatocellular and reticuloendothelial radioiron probes and in iron-loaded rat heart cells in culture.
    Rivkin G, Link G, Simhon E, Cyjon RL, Klein JY, Hershko C.
    Blood; 1997 Nov 15; 90(10):4180-7. PubMed ID: 9354689
    [Abstract] [Full Text] [Related]

  • 2. ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture.
    Hershko C, Konijn AM, Nick HP, Breuer W, Cabantchik ZI, Link G.
    Blood; 2001 Feb 15; 97(4):1115-22. PubMed ID: 11159545
    [Abstract] [Full Text] [Related]

  • 3. Origin and fate of iron mobilized by the 3-hydroxypyridin-4-one oral chelators: studies in hypertransfused rats by selective radioiron probes of reticuloendothelial and hepatocellular iron stores.
    Zevin S, Link G, Grady RW, Hider RC, Peter HH, Hershko C.
    Blood; 1992 Jan 01; 79(1):248-53. PubMed ID: 1728313
    [Abstract] [Full Text] [Related]

  • 4. Determinants of fecal and urinary iron excretion in desferrioxamine-treated rats.
    Hershko C.
    Blood; 1978 Mar 01; 51(3):415-23. PubMed ID: 623907
    [Abstract] [Full Text] [Related]

  • 5. Exploring the "iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture.
    Link G, Konijn AM, Breuer W, Cabantchik ZI, Hershko C.
    J Lab Clin Med; 2001 Aug 01; 138(2):130-8. PubMed ID: 11477380
    [Abstract] [Full Text] [Related]

  • 6. Enhancement of iron chelation by desferrioxamine entrapped in red blood cell ghosts.
    Green R, Miller J, Crosby W.
    Blood; 1981 May 01; 57(5):866-72. PubMed ID: 7214016
    [Abstract] [Full Text] [Related]

  • 7. A rapid assay for evaluation of iron-chelating agents in rats.
    Pippard MJ, Johnson DK, Finch CA.
    Blood; 1981 Oct 01; 58(4):685-92. PubMed ID: 7272500
    [Abstract] [Full Text] [Related]

  • 8. Mechanism of iron chelation in the hypertransfused rat: definition of two alternative pathways of iron mobilization.
    Hershko C, Grady RW, Cerami A.
    J Lab Clin Med; 1978 Aug 01; 92(2):144-51. PubMed ID: 681807
    [Abstract] [Full Text] [Related]

  • 9. Hepatocyte iron kinetics in the rat explored with an iron chelator.
    Pippard MJ, Johnson DK, Finch CA.
    Br J Haematol; 1982 Oct 01; 52(2):211-24. PubMed ID: 7126464
    [Abstract] [Full Text] [Related]

  • 10. Improvement of iron removal from the reticuloendothelial system by liposome encapsulation of N,N'-bis[2-hydroxybenzyl]-ethylenediamine-N,N'-diacetic acid (HBED). Comparison with desferrioxamine.
    Lau EH, Cerny EA, Wright BJ, Rahman YE.
    J Lab Clin Med; 1983 May 01; 101(5):806-16. PubMed ID: 6403640
    [Abstract] [Full Text] [Related]

  • 11. Hemosiderosis in rodents and the effect of acetohydroxamic acid on urinary iron excretion.
    Corden BJ.
    Exp Hematol; 1986 Nov 01; 14(10):971-4. PubMed ID: 3770104
    [Abstract] [Full Text] [Related]

  • 12. Liposome-encapsulated desferrioxamine in experimental iron overload.
    Lau EH, Cerny EA, Rahman YE.
    Br J Haematol; 1981 Apr 01; 47(4):505-18. PubMed ID: 7213574
    [Abstract] [Full Text] [Related]

  • 13. Biliary iron excretion in rats following pyridoxal isonicotinoyl hydrazone.
    Cikrt M, Ponka P, Necas E, Neuwirt J.
    Br J Haematol; 1980 Jun 01; 45(2):275-83. PubMed ID: 7437326
    [Abstract] [Full Text] [Related]

  • 14. Cellular pharmacology of deferrioxamine B and derivatives in cultured rat hepatocytes in relation to iron mobilization.
    Laub R, Schneider YJ, Octave JN, Trouet A, Crichton RR.
    Biochem Pharmacol; 1985 Apr 15; 34(8):1175-83. PubMed ID: 3994740
    [Abstract] [Full Text] [Related]

  • 15. Storage iron kinetics. 3. Study of desferrioxamine action by selective radioiron labels of RE and parenchymal cells.
    Hershko C, Cook JD, Finch DA.
    J Lab Clin Med; 1973 Jun 15; 81(6):876-86. PubMed ID: 4196982
    [No Abstract] [Full Text] [Related]

  • 16. Development and evaluation of the improved iron chelating agents EHPG, HBED and their dimethyl esters.
    Hershko C, Grady RW, Link G.
    Haematologia (Budap); 1984 Jun 15; 17(1):25-33. PubMed ID: 6427069
    [Abstract] [Full Text] [Related]

  • 17. Effects of combined chelation treatment with pyridoxal isonicotinoyl hydrazone analogs and deferoxamine in hypertransfused rats and in iron-loaded rat heart cells.
    Link G, Ponka P, Konijn AM, Breuer W, Cabantchik ZI, Hershko C.
    Blood; 2003 May 15; 101(10):4172-9. PubMed ID: 12511418
    [Abstract] [Full Text] [Related]

  • 18. Deferoxamine inhibition of malaria is independent of host iron status.
    Hershko C, Peto TE.
    J Exp Med; 1988 Jul 01; 168(1):375-87. PubMed ID: 3294334
    [Abstract] [Full Text] [Related]

  • 19. Model of reticuloendothelial iron metabolism in humans: abnormal behavior in idiopathic hemochromatosis and in inflammation.
    Fillet G, Beguin Y, Baldelli L.
    Blood; 1989 Aug 01; 74(2):844-51. PubMed ID: 2502204
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of iron-chelating agents in an in vivo system: potential usefulness of EHPG, a powerful iron-chelating drug.
    Hershko C, Grady RW, Link G.
    Br J Haematol; 1982 Jun 01; 51(2):251-60. PubMed ID: 7082583
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.